Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oza, A. M.
Right arrow Articles by Lister, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oza, A. M.
Right arrow Articles by Lister, T. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:385-392, 1993
© 1993 European Society for Medical Oncology

research-article

Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre

A. M. Oza, T. S. Ganesan, M. Leahy, W. Gregory, J. Lim, L. Dadiotis, V. Barbounis, A. E. Jones, J. Amess, A. G. Stansfeld, A. Z. S. Rohatiner, P. F. M. Wrigley and T. A. Lister

ICRF Department of Medical Oncology, St Bartholomew's Hospital London, U.K

Correspondence to: Prof. T. Andrew Lister, Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE. U.K.

BACKGROUND:: Prolonged remission can now be induced in the majority of patients with Hodgkin's disease with chemotherapy and/or irradiation. However, there is a significant proportion of patients in whom this approach fails, either at presentation or subsequently. Survival is the definitive endpoint to assess treatment efficacy. In this study, the survival patterns of a large group of consecutive patients treated in a single institution are presented.

RESULTS:: The overall median survival was 18.3 years. Clinical remission (complete remission plus good partial remission) was induced in 443 (85%); the median survival of patients in remission has not been reached. Fifty-eight patients achieved responses less than clinical remission with initial therapy (partial response) or had progressive disease, the median survival of this group being 1.4 years. With further therapy, remission was subsequently induced in 10; 5 are still alive, 5 have died between 1.9 years and 14.3 years. Twenty patients died before completion of therapy. Recurrence has been documented in 147 of the patients in remission (following initial therapy) over a median follow up period of 13 years (minimum 5 years). One hundred forty-three of these patients were retreated following recurrence (105 chemotherapy, 28 radiotherapy, 6 combined modality treatment and 4 surgery). Second remission was induced in 109/143 (76%). There was a trend towards better second remission induction in patients whose first remission was longer than 1 year (p = 0.06). The median duration of second remission was inferior to first remission duration (p < 0.001). There was no correlation between duration of first remission and survival following recurrence (p = 0.8) or with duration of second remission (p = 0.54). There was no significant difference in duration of second remission between patients who were initially treated with radiotherapy or chemotherapy (p = 0.3). The median survival following second remission was 12.0 years, being the same for patients with initially localized disease (stages I and II) treated with radiation alone and for patients with advanced Hodgkin's disease (stages III and IV) treated with chemotherapy. Survival after recurrence is significantly better for patients under 50 years at the time of recurrence (p < 0.001). Second recurrence was documented in 46 patients, third remission being reinduced in 22, the median survival of the latter being 5.1 years.

CONCLUSION:: These results illustrate the importance of prolonged follow up in defining the clinical course of patients with HD and are vital for planning experimental chemotherapy at the time of treatment failure or recurrence.

Hodgkin's disease, salvage therapy, recurrence, relapse, resistant disease, chemotherapy, radiotherapy, survival, remission


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. B. Chen, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors
J. Clin. Oncol., November 10, 2009; 27(32): 5383 - 5389.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease
J. Clin. Oncol., September 1, 2006; 24(25): 4116 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hutchings, A. Loft, M. Hansen, L. M. Pedersen, T. Buhl, J. Jurlander, S. Buus, S. Keiding, F. D'Amore, A.-M. Boesen, et al.
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Blood, January 1, 2006; 107(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Hutchings, N. G. Mikhaeel, P. A. Fields, T. Nunan, and A. R. Timothy
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
Ann. Onc., July 1, 2005; 16(7): 1160 - 1168.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.